Visgenx is developing therapeutics based on increasing expression of a gene known as ELOVL2 which has been shown to regulate aging in the retina and other tissues. Our lead indication is Dry Age-Related Macular Degeneration (Dry AMD).
Company Details
- Employees
- 2
- Founded
- 2018
- Address
- 250 Natural Bridges Dr, Santa Cruz,california 95060,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.visgenx.com
- Keywords
- Gene Therapy.
- HQ
- Santa Cruz, California
Visgenx Questions
Visgenx's website is http://www.visgenx.com
Visgenx's LinkedIn profile is https://www.linkedin.com/company/visgenx
Visgenx has
2 employees.
View email and phone details for 2
employees at Visgenx.
Visgenx's industry is
Biotechnology Research
Visgenx's top competitors are
Oncopep, Inc.,
Annexon Biosciences,
Iacta Pharmaceuticals,
Hall Estill,
Glaukos Corporation,
Nanoscope Therapeutics Inc.,
Visgenx, Inc,
Lucina Biotherapeutics,
Palm Therapeutics,
Papillon Therapeutics.
Visgenx's categories are Biotechnology Research
Visgenx's founding year is 2018
